[en] Colorectal cancer is the third most common form of cancer in Europe, Its prognosis is poor, since median survival time for metastatic patients is about 20 months. Progresses in molecular biology have lead to significant improvement in the management of metastatic colorectal cancer with targeted therapies. The monoclonal antibodies anti-EGFR and anti-VEGFR improve the overall and the progression-free survival. The anti-EGFR antibodies (cetuximab and panitumumab) have been marketed in Belgium, as monotherapy or in association with chemotherapy (FOLFIRI) for third line use in patients with wild type K-ras. The anti-VEGFR bevacizumab is the standard first line treatment in metastatic colorectal cancer with irinotecan based chemotherapy. For the future, the place of monoclonal antibodies therapies in adjuvant or in first line settings and the value of combining targeted therapies have to be further defined.
Disciplines :
Oncology
Author, co-author :
Piront, Patricia ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
VAN DAELE, Daniel ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Belaiche, Jacques ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques
POLUS, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Language :
French
Title :
Apports des anticorps monoclonaux dans le traitement du cancer colorectal: cetuximab, panitumumab et bevacizumab.
Alternative titles :
[en] Monoclonal antibodies therapies for colorectal cancer: cetuximab, panitumumab and bevacizumab
Publication date :
2009
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Baselga J.- The EGFR as a target for anticancer therapy: focus on cétuximab. Eur J Cancer, 2001, 37, S16-S22.
Cunningham D, Humblet Y, Siena S, et al.- Cétuximab monotherapy and cétuximab plus irinotecan in irinitecan refractory metastatic colorectal cancer. N Engl J Med, 2004, 35, 337-345.
Jonker D, O'Callaghan C, Karapetis C, et al.- Cétuximab for the treatment of cancer colorectal. N Engl J Med, 2007, 357, 2040-2048.
Van Cutsem E, Nowacki M, Lang I, et al.- Efficacy and safety of irinotecan and 5-FU/FA with and without cétuximab in first line treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol, 2007, 25, 164s, abstract 4000.
Van Cutsem E, Lang I, D'haens G, et al.- K-ras status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cétuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol, 2008, 26, 5s, abstract 2.
Bokemeyer C, Bondarenko I, Makhson A, et al.- Fluorouracil, Leucovorin, and Oxaliplatin with an without Cétuximab in the First-Line treatment of metastatic colorectal cancer. J Clin Oncol, 2009, 27, 663-671.
Van Cutsem E, Peeters M, Siena S, et al.- Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J Clin Oncol, 2007, 25, 1658-1664.
Peeters M, Siena S, Van Cutsem E, et al.- Association of progression-free-survival, overall survival, and patient-reported outcomes by skin tocicity and Kras status in patients receiving panitumumab monotherapy. Cancer, 2009, 115, 1544-1554.
Lièvre A, Bachet JB, Boige V, et al.- KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cétuximab. J Clin Oncol, 2008, 26, 374-379.
Karapetis C, Khambata S, Jonker D, et al.- K-ras mutations and benefit from cétuximab in advanced colorectal cancer. N Engl J Med, 2008, 359, 1757-1765.
Amado RG, Wolf M, Peeters M, et al.- Wild-type K-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26, 1626-1634.
Tokunaga T, Oshika Y, Abe Y, et al.- Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis et poor prognosis in colon cancer. Br J Cancer, 1998, 77, 998-1002.
Carmeliet P.- VEGF as a key mediator of angiogenesis in cancer. Oncology, 2005, 69, 4-10.
Andre T, Tournigand C, Abbas F, et al.- Traitement anti angiogénique et cancer colorectal. Bull cancer, 2007, 94, S211-219.
Kabbinavar F, Hambleton J, Mass R, et al.- Combined analysis of efficacy : the addition of bévacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol, 2005, 23, 3706-3712.
Hurwitz H, Fehrenbahcer L, Novotny W, et al.- Bévacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350, 2335-2342.
Giantonio B, Catalano P, Meropol N, et al.- Bévacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX 4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology group study. J Clin Oncol, 2007, 25, 1539-1544.
Grothey A, Sugrue MM, Purdie DM, et al.- Bévacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : results from a large observational cohort study (BRITE). J Clin Oncol, 2008, 26, 5326-5334.
Berry S, Van Cutsem E, Kretzschmar A, et al.- Final efficacy results for Bévacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. Proc Am Soc Clin Oncol, 2008, 26, 184s, abstract 4025.
Hecht JR, Trarbach J, Jaeger E, et al.- A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first line chemotherapy with Oxaliplatin, 5-fluorouracil, leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol, 2005, 23, 2s, LBA3.
Koehne C, Bajetta E, Lin E, et al.- Results of an interim analysis of a multinational, double-blind, phase III study in patients with previously treated metastatic colorectal cancer receiving Folfox 4 and PTK787/ZK222584 or placebo (CONFIRM 2). Proc Am Soc Clin Oncol, 2006, 24, 148s, abstract 3508.
Tol J, Koopman M, Cats A, et al.- Chemotherapy, bévacizumab, and cétuximab in metastatic colorectal cancer. N Engl J Med, 2009, 360, 563-572.
Hecht JR, Mitchell E, Chidiac T, et al.- A randomized phase IIIb trial of chemotherapy, bévacizumab, and panitumumab compared with chemotherapy and bévacizumab alone for metastatic colorectal cancer. J Clin Oncol, 2009, 27, 672-680.
Punt CJ, Tol J, Rodenburg CJ, et al.- Randomized phase III study of Capecitabine, Oxaliplatin, and Bévacizumab with or without Cétuximab in advanced colorectal cancer, the CAIRO2 study of the DutchColorectal Cancer Group (DCCG). Proc Am Soc Clin Oncol, 2008, 26, 180s abstract LBA4011.
